

## Summary Table

Table 1. Survival outcomes and prevalence of clinico-pathological characteristics according to TILs.

	Studies	TILs			c <sup>2</sup>
		Brisk	Non-Brisk	Absent	
<b>Survival outcomes</b>					
5-year overall survival	5	84% (80%-89%)	68% (57%-78%)	61% (48%-72%)	p=0.02
5-year disease-free survival	2	87% (73%-94%)	80% (62%-90%)	67% (60%-74%)	p=0.03
5-year melanoma-specific survival	3	94% (88%-97%)	90% (82%-94%)	88% (77%-94%)	p=0.34
10-year overall survival	2	79% (26%-98%)	51% (39%-64%)	40% (17%-69%)	p=0.43
<b>Clinico-pathological characteristics</b>					
Breslow					
I	4	52% (26%-78%)	47% (21%-74%)	43% (20%-69%)	p=0.89
II	4	26% (14%-45%)	20% (10%-36%)	19% (11%-30%)	p=0.68
III	4	11% (6%-20%)	15% (9%-24%)	17% (10%-26%)	p=0.60
IV	4	4% (1%-15%)	10% (6%-18%)	9% (6%-14%)	p=0.20
Lymphatic invasion	3	24% (9%-50%)	41% (34%-39%)	83% (36%-100%)	P=0,08
Positive sentinel lymph nodes	6	13% (5%-33%)	13% (8%-19%)	14% (8%-22%)	p=0.95
Histologic ulceration	10	17% (10%-26%)	25% (18%-32%)	21% (15%-29%)	p=0.39
Perineural infiltration	1	3% (0%-17%)	5% (1%-12%)	-	p=0.74
Vascular invasion	3	14% (1%-78%)	24% (2%-84%)	12% (11%-15%)	p=0.86

DFS: disease-free survival OS: overall survival.

## Risk of bias of the included studies

According to the Newcastle-Ottawa quality assessment form, the risk of bias of the 16 eligible studies was critically evaluated, as in Table 2.

Table 2. Risk of bias of the 16 eligible studies.

PMID	STUDY	Total score (0-9)
8608507	Clemente et al, 1996	8
12375635	Tuthill et al, 2002	7
17327608	Taylor et al, 2007	7
19553103	Mandalà et al, 2009	6
20231618	Rao et al, 2010	6
21337878	Burton et al, 2011	7
24127443	Thomas et al, 2013	6
25550571	Dionizy et al, 2015	6
27473267	Weiss et al, 2016	6
28368925	Saldanha et al, 2017	6
33455116	Gata et al, 2020	6
34153563	Zaladonis et al, 2021	6
34550383	Yang et al, 2021	6
35103302	Morrison et al, 2022	7
35301610	Straker et al, 2022	7